Summary: In a 12-week, three-arm pilot randomised controlled trial of 30 adults with type 2 diabetes, an 800 kilocalorie per day very-low calorie diet (VLCD) and a VLCD-plus-semaglutide combination produced significantly greater reductions in body weight and fat mass than semaglutide alone (p < 0.01 versus both), with VLCD and the combination giving 5.4 and 7 percentage points more weight loss respectively. Adding semaglutide to the VLCD conferred no additive weight benefit over VLCD alone but was associated with greater improvement in pancreatic beta-cell function. As an exploratory pilot, these findings are hypothesis-generating rather than confirmatory.
PICO Summary
| Element | Detail |
|---|---|
| Population | 30 adults (aged 18 to 75 years, BMI 27 to 50 kg/m2) with type 2 diabetes; single-centre pilot randomised controlled trial conducted in the United Kingdom. |
| Intervention | Very-low calorie diet (800 kcal/day, VLCD arm) or VLCD plus semaglutide (combination, COMB arm) for 12 weeks; approximately 10 participants per arm. |
| Comparison | Semaglutide alone (SEM arm), titrated standard dosing, for 12 weeks; approximately 10 participants. |
| Outcome | Body weight and fat mass fell significantly more with VLCD and COMB than with SEM (p < 0.01 versus both); VLCD and COMB gave 5.4 and 7 percentage points greater weight loss than SEM respectively. HbA1c and fasting glucose decreased in all arms, while fasting insulin and HOMA-IR improved only with VLCD and COMB. The first-phase insulin response on intravenous glucose tolerance testing rose in SEM and COMB, with a significantly greater rise in COMB than VLCD (p < 0.01). COMB gave no additive weight or body-composition benefit over VLCD alone. No 95% confidence intervals, absolute risk reduction, or number-needed-to-treat were reported for this small exploratory trial. |
VLCD, semaglutide, or both in type 2 diabetes
Pilot RCT · type 2 diabetes · 12 weeks
VLCD drove markedly greater weight and fat-mass loss than semaglutide over 12 weeks; adding semaglutide gave no extra weight loss but improved beta-cell function. Hypothesis-generating pilot only.
Expert Commentary
This pilot trial is best read as hypothesis-generating rather than practice-changing. The headline signal is coherent and biologically plausible: a marked caloric deficit drives weight and fat-mass loss more effectively over 12 weeks than semaglutide at the doses used, while the addition of semaglutide to the diet appears to sharpen pancreatic beta-cell recovery without adding to weight loss. The verdict is that combination therapy is a promising avenue that has not yet been shown to deliver clinically meaningful incremental benefit. The dominant limitation is statistical fragility: with roughly ten participants per arm, an open-label design, and a 12-week horizon, the trial is underpowered for durable glycaemic or cardiometabolic endpoints, and no confidence intervals were reported, so the precision of these between-group differences is unknown. The unblinded structure also leaves dietary-adherence and expectation effects uncontrolled. Can I use this with my patients? Not yet as a protocol, though it reasonably reinforces that an aggressive dietary deficit remains a powerful lever in motivated, closely supervised adults with type 2 diabetes. Larger, longer, adequately powered trials with confidence intervals and weight-maintenance follow-up are needed before a sequenced diet-plus-semaglutide strategy can be recommended. The relevant beta-cell finding deserves dedicated study.
References
Anyiam O, Phillips B, Quinn K, Wilkinson D, Smith K, Atherton P, Idris I. Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus. Clin Nutr. 2024;43(8):1907-1913. doi:10.1016/j.clnu.2024.06.034